Shoulder Innovations Earnings Call Transcripts
Fiscal Year 2026
-
Exclusive partnerships and innovative product launches are expanding the addressable market, with robotics and software advancements set to drive future growth. Strong commercial execution and clinical outcomes support raised financial guidance and margin expansion, while scalable education and a collaborative culture underpin continued market penetration.
-
Shoulder arthroplasty is experiencing rapid growth, driven by a shift to outpatient care and innovative solutions like the InSet Glenoid and AI-enabled planning. The company’s focused commercial model, robust product pipeline, and cost-efficient operations position it for continued market share gains and expansion opportunities.
-
Q2 2026 revenue grew 56% YoY to $17.2M, with gross margin at 78.3% and improved net loss. Full-year guidance was raised to $67M–$69M, reflecting robust customer growth, strong product launches, and continued operational efficiency. Cash position remains strong at $99M.
-
The meeting was held virtually, confirming quorum and presenting two proposals: director elections and auditor ratification. Both proposals passed by the required votes, with no questions from stockholders. Final results will be filed with the SEC.
-
Q1 2026 saw 65% revenue growth and gross margin expansion to 77.7%, driven by strong surgeon adoption and new product launches. Full-year revenue guidance was raised to $65–$68 million, with continued investment in innovation and commercial scale.
-
Shoulder arthroplasty is experiencing rapid growth, driven by innovative implants, AI-enabled planning, and a shift to outpatient procedures. New product launches and a robotics-as-a-service model are set to further differentiate offerings and support expansion beyond the U.S.
Fiscal Year 2025
-
Revenue grew 65% in Q4 and 50% for the year, driven by rapid surgeon adoption and new product launches. 2026 guidance projects 31–37% revenue growth, with strong gross margins and continued investment in robotics and commercial expansion.
-
Leadership leverages decades of experience to drive innovation in shoulder arthroplasty, with strong growth among high-volume surgeons and a focus on portable, ASC-friendly robotics. Financial outlook remains positive, with robust margins and plans to expand indications in 2026.
-
Operating in a $2.8B global market, the company leverages innovative implant and AI planning technologies to address key clinical challenges and ASC logistics. Recent regulatory wins and new product launches are set to expand market reach and improve margins.
-
Q3 revenue rose 58% year-over-year to $11.8M, with gross margin at 76.2% and strong cash reserves of $137M. Full-year guidance was raised to $45–$46M, reflecting robust adoption, new product launches, and continued expansion in high-volume surgeon users.
-
The company is rapidly expanding in the U.S. shoulder arthroplasty market, leveraging a capital-efficient two-tray system, AI-enabled planning, and a hybrid sales model. Strong Q2 growth, robust IPO funding, and high surgeon engagement position it for continued momentum and innovation.